80mg/ml solution for injection in pre-filled syringe or pen
In the event of an inadvertent temperature excursion the following data may be used:
Taltz may be stored unrefrigerated for a cumulative duration of 5 days at a temperature not above 30°C.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Contact Eli Lilly in all other cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company details.
No, if exposed to the conditions above
Yes, if exposed to the conditions above
29 September 2021
London MI Service
Taltz · Moderate to severe chronic plaque psoriasis in children aged 6-17 years
Licence extension / variation
Development and Regulatory status
Phase III Clinical Trials
Jul 20 · Approved in the EU and UK .
May 20 · Recommended for EU approval by CHMP - the additional indication is "for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy." 
Humanized anti–interleukin-17 monoclonal antibody
Prevalence of psoriasis in childhood in the UK is about 0.55 % in children aged 0–9 years and 1.37 % in children aged 10–19 years .
Moderate to severe chronic plaque psoriasis in children aged 6-17 years